Basic Information
| LncRNA/CircRNA Name | H19 |
| Synonyms | NA |
| Region | GRCh38_11:1995176-2001470 |
| Ensemble | ENSG00000130600 |
| Refseq | NR_002196 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | endometrial cancer |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, Dual Luciferase Reporter Gene Assay |
| Sample | endometrial cancer tissues, cell lines(HEC1-A, HEC1-B, AN3CA, Ishikawa) |
| Expression Pattern | up-regulated |
| Function Description | The expression of lncRNA H19 and HOXA10 was high in endometrial carcinoma and miR-612 was lowly expressed. The survival curve suggested that lncRNA H19 was negatively correlated with patient survival.The high expression of lncRNA H19 in endometrial carcinoma may regulate the expression level of its target gene HOXA10 by targeting miR-612, thus promoting cell proliferation to play a role in the development of endometrial carcinoma. |
| Pubmed ID | 30070313 |
| Year | 2018 |
| Title | LncRNA H19 Regulates the Expression of Its Target Gene HOXA10 in Endometrial Carcinoma Through Competing With miR-612. |
External Links
| Links for H19 | GenBank HGNC NONCODE |
| Links for endometrial cancer | OMIM COSMIC |